Meloset can be used off-label to help adjust the sleep schedule of night-shift workers, but the timing of the dose must align with the desired sleep period. It is advisable to discuss a tailored dosing plan with a clinician, as the optimal timing differs from the typical bedtime administration.
Melatonin is not a controlled substance and is not typically screened for in standard occupational drug tests. However, some specialized panels may include it; verify with the testing laboratory if you have concerns.
Each 3 mg Meloset tablet is imprinted with the letters “M-3” on one side, indicating the brand and strength. Appearance may vary slightly between batches, but the imprint remains consistent for identification.
Yes, but you should carry the original prescription or a doctor’s letter, and keep the medication in its original labeled container. Check the destination country’s import rules, as some may require additional documentation for prescription-only medicines.
Both melatonin and valerian have sedative properties; combining them may increase drowsiness. Consult a healthcare professional before using them together to avoid excessive sedation.
Tablets remain stable when stored as directed; opening the bottle does not affect potency as long as the cap is replaced promptly and the tablets are kept away from moisture and heat. Use them before the expiry date printed on the packaging.
Meloset is a prescription-only product with a precisely regulated 3 mg dose and strict manufacturing standards verified by the MHRA. Over-the-counter supplements may vary in dose, purity, and quality, and are not evaluated by the same regulatory process.
Melatonin can sometimes lower blood pressure, especially when taken at night. If you are on antihypertensive drugs, your physician may monitor your blood pressure after starting Meloset and adjust doses if necessary.
Older adults typically experience a natural decline in melatonin production, making supplementation more beneficial. The safety and efficacy of melatonin in younger adults have not been established to the same degree for this specific formulation, prompting regulatory restriction.
Melatonin is not considered habit-forming, and there is no evidence of physiological dependence. However, psychological reliance on any sleep aid should be addressed with a clinician to ensure healthy sleep habits are maintained.
Meloset is a prescription-only medication (POM) marketed in the United Kingdom for the short-term treatment of insomnia. Each tablet contains 3 mg of melatonin, a hormone naturally produced by the pineal gland that helps regulate the body’s sleep-wake cycle. Meloset is supplied as an oral pill and is intended for adult patients who have difficulty initiating or maintaining sleep.
The Medicines and Healthcare products Regulatory Agency (MHRA) authorises melatonin products for use in adults aged 55 years or older, reflecting the reduced endogenous melatonin production that commonly occurs with aging. The brand name “Meloset” distinguishes this formulation from other melatonin preparations that may be available as over-the-counter supplements.
Melatonin exerts its sleep-promoting effects by acting as an agonist at melatonin receptors MT1 and MT2 located in the suprachiasmatic nucleus (SCN) of the hypothalamus. The SCN serves as the body’s master clock, coordinating circadian rhythms such as hormone release, body temperature, and alertness.
When taken ~30-60 minutes before bedtime, the 3 mg dose of melatonin in Meloset supplements the declining endogenous levels that occur in the evening, reinforcing the natural signal that it is time to sleep. This results in:
Melatonin is rapidly absorbed from the gastrointestinal tract, reaching peak plasma concentrations within 30-60 minutes. It is metabolised primarily by the liver enzyme CYP1A2 and excreted in the urine as 6-hydroxymelatonin sulfate. The relatively short half-life (≈ 30-50 minutes) limits the risk of next-day residual sedation.
Meloset is licensed in the UK for the short-term treatment of primary insomnia in adults aged 55 years and older. Clinical trials supporting its approval demonstrated that a 3 mg nightly dose can reduce sleep latency by an average of 10-15 minutes and increase total sleep time without significant next-day sedation.
Typical patient profiles include:
Meloset is not indicated for chronic insomnia lasting longer than three weeks, nor is it approved for use in children, adolescents, or adults under 55 years without a specialist’s prescription.
Although not formally licensed for these indications in the UK, melatonin (and therefore Meloset) has been investigated for several off-label applications. The evidence varies in strength, and any such use must be supervised by a qualified healthcare professional.
Randomised controlled trials have shown that melatonin taken at the target bedtime in the new time zone can speed the realignment of circadian rhythms, reducing jet-lag symptoms such as daytime sleepiness and nighttime wakefulness. Doses of 0.5-5 mg taken at the appropriate local time have been studied, with 3 mg being a common regimen.
Regulatory status: Not approved for jet-lag treatment in the UK; usage is off-label.
Limited data suggest that low-dose melatonin (0.5-2 mg) administered several hours before the desired bedtime can advance the sleep phase in individuals with DSPD. Higher doses, such as the 3 mg in Meloset, are occasionally used when lower doses are ineffective, but robust comparative trials are lacking.
Regulatory status: Off-label; requires specialist assessment.
All off-label uses should be discussed with a prescribing clinician, who can weigh potential benefits against the limited evidence base.
Most of these events are reported in > 1 % of users in clinical studies and tend to diminish after the first few nights of therapy.
If you are taking other medicines, supplements, or herbal products, inform your prescriber before starting Meloset.
Special population adjustments
This article provides educational information about Meloset and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
